Jiangxi Sanxin Medtec Co (300453) Fair Value & Analysis
Healthcare · CN · Market cap 4.8B CNY
Fair value as of: Jul 9, 2026
From 26 valuation models · updated 32 days ago
Fair value updated Jul 9, 2026, revised from ¥11.06 to ¥10.70 (−3.3%) since Jun 24, 2026. Share price +0.8% over the past month.
A solid business, screening 12% undervalued on our models.
What matters now
- Our model range runs from ¥7.65 (bear) to ¥13.33 (bull), base ¥10.70. The closer the price sits to the lower half, the larger the margin of safety.
- Quality 65/100 (solid quality) with medium evidence: read the verdict with care.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 9, 2026.
How to read this chart
60‑month range ¥4.63 – ¥11.32 · fair‑value band ¥7.65 – ¥13.33 · the ¥9.55 price screens below the ¥10.70 fair value. Dashed = 300-day average. As of Jul 9, 2026.
Analysis
Jiangxi Sanxin Medtec Co (300453) currently trades at ¥9.55, while our model-based Fair Value estimate is ¥10.70, implying the stock looks roughly 12.0% undervalued today. The Quality Score stands at 65/100 (solid quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: medium), always confirm before acting.
Over the trailing twelve months, Jiangxi Sanxin Medtec Co generated revenue of 1.7B CNY at a net margin of 16.6%. Revenue grew 13.4% year over year. It earns a return on equity of 19.8%. The balance sheet holds a net cash position of 92.0M CNY. Fundamentals as of Jul 9, 2026
Our scenario range runs from ¥7.65 (bear case) to ¥13.33 (bull case); at ¥9.55, the current price sits within that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 15% below its 52-week high and 28% above its 52-week low, currently above its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -43% fair-value upside, at 12%, 300453 screens cheaper than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 26 models by family
Widest divergence: Growth Earnings (¥11.98) versus Asset-Based (¥1.87). Highest evidence: Growth DCF (80).
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Jul 9, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 65 · Market factors (momentum, volatility) 60
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Jiangxi Sanxin Medtec Co.,Ltd. engages in the research and development, manufacture, sale, and service of medical devices.
Full company description
Jiangxi Sanxin Medtec Co.,Ltd. engages in the research and development, manufacture, sale, and service of medical devices. The company offers infusion and cardiothoracic surgery products; and blood purification products, such as dialysate filter, dialysis indwelling needle, disposable biological protein glue dispenser, dialysis fluid filter, continuous blood purification pipeline and accessories, hemodialysis concentrate, hemodialysis water production systems, hemodialysis machines, centralized liquid supply system, dialysis care package, central venous catheter kits, arteriovenous spikes, accessories tubing for HDF, dialysate filters, hemodialysis dry powders and concentrates, disposable hollow fiber dialyzers, blood purification and fluid replacement pipeline, and hemodialysis tubing. It also provides pre filled catheter flushing device, heparin cap, sterile needle, disposable filtration infusion set, disposable light shielded precision filtration infusion set, blood transfusion device, infusion disinfection connector, Y-shaped indwelling needle, closed vein indwelling needle, pneumatic needle free injector, insulin syringe, injection needle, dispensing syringe, disposable sterile syringe, fixed dose vaccine injector, extension tube, positive pressure venous indwelling needle, and self-destructible syringe. In addition, the company offers right heart suction head, cardiopulmonary bypass connector, blood clot filter, cold pump infusion device, artificial heart lung extracorporeal circulation pipeline package, and disposable blood storage filter. Further, it provides disposable balloon expansion pressure pump, vascular sheath group, and PTA high-pressure balloon dilation catheter, as well as medical needle free injector. Jiangxi Sanxin Medtec Co.,Ltd. was founded in 1997 and is headquartered in Nanchang, China.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Jiangxi Sanxin Medtec Co reported revenue of ¥1.6B in FY2025 versus ¥1.2B in FY2021, a compound +8.9%/yr. Reported net income was ¥262M in FY2025, compounding +13.9%/yr from FY2021.
Watch 300453: get an alert when its fair value changes →
Peer Group
Medical Instruments & Supplies · 203 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Medical Instruments & Supplies median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Medical Instruments & Supplies stocks, each showing price versus our Fair Value estimate (as of Jul 9, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Intuitive Surgical, Inc ISRG | $402.33 | $150.04 | -63% |
| EssilorLuxottica Société anonyme 1EL | €172.45 | €68.55 | -60% |
| Medline Inc MDLN | $41.11 | $30.15 | -27% |
| Becton, Dickinson and Company BDX | $150.65 | $103.53 | -31% |
| Alcon Inc ALC | $70.26 | $39.78 | -43% |
| ResMed Inc RMD | $203.87 | $187.89 | -8% |
| West Pharmaceutical Services, Inc WST | $353.71 | $143.97 | -59% |
| Straumann Holding STMN | CHF 106.00 | CHF 47.31 | -55% |
| Sartorius Stedim Biotech S.A DIM | €188.50 | €51.16 | -73% |
| Coloplast A/S COLOB | kr 414.00 | kr 382.22 | -8% |
Compare Jiangxi Sanxin Medtec Co with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Jiangxi Sanxin Medtec Co (300453) overvalued or undervalued?
What is the fair value of 300453?
What is the quality score of 300453?
What is the revenue of Jiangxi Sanxin Medtec Co (300453)?
What is the net profit margin of 300453?
Does Jiangxi Sanxin Medtec Co pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Jiangxi Sanxin Medtec Co and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.